Pneumatic Retinopexy — Office-Based Retinal Detachment Repair Guide — Cost, Top Hospitals & Success Rates | MyMedicPlus

Pneumatic retinopexy (note: the correct spelling is pneumatic, from the Greek pneuma — air) is a minimally invasive, office-based procedure for the repair of rhegmatogenous retinal detachment (RRD) — retinal detachment caused by a full-thickness break through which liquefied vitreous gains access to the subretinal space and separates the neurosensory retina from the retinal pigment epithelium (RPE).

The procedure was first described by Hilton and Grizzard in 1986 and involves two key principles: (1) intravitreal injection of an expansile gas bubble to tamponade the causative retinal break and allow resorption of subretinal fluid, and (2) retinopexy — the creation of a chorioretinal adhesion around the break using trans-conjunctival cryotherapy or laser photocoagulation — to permanently seal the break and prevent recurrence.

The therapeutic logic is elegant: the injected gas bubble — being lighter than the vitreous humour and aqueous — rises to the highest point of the eye. By positioning the patient so that the causative retinal break sits at the highest point (uppermost position), the bubble presses against the break from the vitreous side, preventing further subretinal fluid ingress and allowing the RPE pump to reabsorb existing subretinal fluid over 1–7 days. As the retina reattaches, laser or cryo adhesion permanently seals the break.

Compared to the operating theatre-based alternatives — scleral buckling and pars plana vitrectomy (PPV) — pneumatic retinopexy offers significant advantages in terms of cost, access, and preservation of the crystalline lens. It does not require general or regional anaesthesia, hospitalization, or complex surgical equipment, making it particularly valuable in settings where operating theatre access is limited.

Pneumatic retinopexy is indicated specifically for rhegmatogenous retinal detachment (RRD) and does not treat tractional (diabetic, sickle cell) or exudative (choroidal tumour, uveitis) retinal detachments. Within RRD, appropriate case selection is critical to procedural success.

Superior retinal breaks causing RRD: The classical and most evidence-supported indication. Breaks located in the superior 8 clock hours (10 o'clock to 2 o'clock) are ideally tamponaded by the rising gas bubble when the patient maintains upright or face-down positioning, and carry the best success rates (70–80% single-procedure).

Types of causative breaks treated:

• U-tears (horseshoe tears): Symptomatic tears with posterior vitreous detachment-related flap formation are the most common type treated. A single U-tear within 1 clock hour with superior location is ideal.
• Round holes: Atrophic round holes in phakic or pseudophakic eyes; typically smaller than U-tears and well-suited to pneumatic retinopexy
• Operculated holes: Holes with the operculum still attached or free-floating; generally amenable to pneumatic retinopexy
• Pseudophakic and aphakic RRD: Post-cataract surgery detachments are a common setting; pneumatic retinopexy performs well particularly with single superior breaks

Conditions where pneumatic retinopexy is less suitable or contraindicated:

• Inferior retinal breaks (below the 4 o'clock to 8 o'clock meridian) — the gas bubble cannot adequately tamponade these breaks regardless of positioning
• Multiple breaks in different clock-hour locations not coverable by a single gas bubble
• Breaks spanning more than 1 clock hour in total arc
• Proliferative vitreoretinopathy (PVR) grade C or D — traction from membranes prevents retinal reattachment
• Significant vitreous haemorrhage obscuring view and preventing retinopexy
• Significant lattice degeneration surrounding the break that is inaccessible to cryo or laser

Patient selection is the most critical determinant of success in pneumatic retinopexy. Careful pre-operative slit-lamp biomicroscopy and indirect ophthalmoscopy with scleral depression to identify all breaks, lattice degeneration, and PVR is mandatory before proceeding.

Favourable eligibility criteria for pneumatic retinopexy (the ‘classic’ selection criteria):

• Single retinal break (U-tear, round hole, or operculated hole) located in the superior 8 clock hours of the fundus (8 o'clock to 4 o'clock via the top)
• Break size no greater than 1 clock hour in total arc extent
• All identifiable breaks are within 1 clock hour of each other (coverable by a single bubble)
• Minimal or no PVR (PVR grade A or B only — the presence of established periretinal membranes contradicts pneumatic retinopexy)
• Patient is able to maintain required head positioning reliably for 5–7 days post-injection
• Patient is phakic or pseudophakic (aphakic eyes with large vitreous base breaks are higher failure risk)
• No contraindication to gas injection (planned air travel within gas absorption period is an absolute contraindication — gas bubble expands at altitude, risking acute glaucoma)

Additional considerations:

• Macula status: pneumatic retinopexy can be performed for both macula-on (urgent procedure, within 24 hours) and macula-off RRD (within days of macula detachment), though macula-off detachments carry worse final visual acuity regardless of reattachment method
• The pupil must be dilatable sufficiently to allow full fundal examination and laser photocoagulation coverage
• Patient compliance with face-down or target positioning is essential; elderly, obese, or those with musculoskeletal limitations may struggle with prolonged positioning and may be better candidates for vitrectomy
• General anaesthesia contraindication: pneumatic retinopexy is an excellent option for patients who are poor surgical anaesthetic risks, since it requires only topical and subconjunctival local anaesthesia

Pre-operative preparation: Detailed fundal mapping under indirect ophthalmoscopy with scleral depression identifies all breaks and their clock-hour locations, the extent of subretinal fluid, macula status, vitreoretinal traction, and presence of PVR. This map guides patient positioning post-injection. Pupils are dilated. Topical and subconjunctival anaesthesia (2% lignocaine with adrenaline) is administered.

Intraocular pressure reduction: To create room for the gas injection and prevent dangerous IOP elevation, anterior chamber paracentesis is performed using a 27–30-gauge needle at the limbus to remove 0.2–0.3 mL of aqueous. IOP is checked by tonometry before gas injection.

Gas injection: The two most commonly used gases are:

• Sulfur hexafluoride (SF6): Injected as a 14–20% mixture in air (total volume 0.3–0.5 mL). Non-expansile at these concentrations. Absorption time: 7–14 days. Provides adequate tamponade for most cases, shorter recovery time.
• Perfluoropropane (C3F8): Injected as a 12–16% mixture in air (0.3 mL). Absorbs over 4–8 weeks — longer tamponade, preferred for larger breaks or where more time for retinopexy adhesion is desired. Expansile until equilibrium is reached — patients must not fly or ascend to high altitude until the bubble has fully resorbed.

The gas is injected through the pars plana (3.5–4 mm from limbus in phakic, 3 mm in pseudophakic) using a 30-gauge needle. The eye is checked for light perception and optic disc perfusion after injection to ensure central retinal artery is patent.

Retinopexy — Cryotherapy vs. Laser:

• Trans-conjunctival cryotherapy: Applied immediately before or after gas injection; the cryo probe is applied through the conjunctiva and sclera to the retinal break under indirect ophthalmoscopic visualisation. Produces a white ice ball at the break site. Adhesion forms within 48–72 hours. Preferred when the break cannot be well-visualised through gas (due to media opacity) and when subretinal fluid overlies the break.
• Laser photocoagulation: Applied at the slit-lamp or indirect laser delivery system 24–48 hours after gas injection, once the break rises to the superior retinal position and is accessible for laser. Laser creates a scar ring of 2–4 rows of confluent burns around all break margins. Produces durable adhesion within 1–2 weeks. Generally preferred over cryo when possible due to more controlled application and lower PVR-induction risk.

Post-injection positioning: The patient is instructed to maintain the break-up (uppermost) position for a minimum of 5–7 days continuously (including during sleep, using a face-down chair or stacked pillow supports). Day 1 review is essential to confirm bubble-break contact, assess IOP, and initiate laser if conditions are suitable.

Pneumatic retinopexy offers a distinctive combination of advantages that make it a compelling first-choice procedure in appropriately selected patients with RRD.

Office-based, no theatre required: The procedure is performed in an outpatient clinic or office setting under local anaesthesia. This eliminates surgical theatre scheduling delays, reduces exposure to general anaesthetic risks, and dramatically improves access in healthcare systems where ophthalmology theatre time is constrained — enabling truly urgent intervention within hours of diagnosis in macula-on RRD.

Single-procedure success rates: In ideal candidates — single superior break, no PVR, reliable positioning — published series consistently report initial anatomical reattachment success of 70–80%. The PIVOT trial (Pan-American Collaborative Retina Study Group) randomised 176 eyes with superior RRD to pneumatic retinopexy versus 20-gauge vitrectomy and demonstrated that although single-procedure anatomical success was lower for pneumatic retinopexy (76% vs. 90% for vitrectomy), final visual acuity at 12 months was equivalent between groups — and pneumatic retinopexy patients achieved faster visual recovery in the early post-operative period.

Lens preservation: Unlike phaco-vitrectomy combined procedures, pneumatic retinopexy does not disturb the crystalline lens, preserving accommodation in phakic patients and avoiding the risk of accelerating nuclear sclerotic cataract that occurs in nearly all phakic patients after pars plana vitrectomy.

Cost-effectiveness: Pneumatic retinopexy is substantially less expensive than vitrectomy or scleral buckling — typically 40–70% less in total healthcare system cost — due to elimination of theatre time, anaesthesia, and hospitalisation.

Rapid visual recovery: Many patients notice visual improvement within 1–2 weeks of successful reattachment, with final visual acuity outcomes for macula-on detachments approaching pre-detachment levels in the majority of cases.

Pneumatic retinopexy has a distinct complication profile related to both the gas injection itself and the inherent nature of the procedure.

Procedural failure (re-detachment): The most significant risk. Approximately 20–30% of cases fail after a single procedure, most commonly due to:

• Missed breaks not identified on pre-operative examination — the commonest cause; missed inferior or peripheral breaks undetected before injection subsequently open once subretinal fluid shifts
• Inadequate retinopexy coverage — incomplete cryotherapy or laser application failing to seal all break margins
• Non-compliance with positioning — the gas bubble fails to maintain contact with the break if positioning is inadequate
• New breaks forming in fellow-eye or treated eye lattice degeneration after gas injection
• PVR development — epiretinal membrane formation with traction re-opening sealed breaks; occurs in 3–8% after pneumatic retinopexy, somewhat higher than after vitrectomy

Intraocular pressure elevation: Gas expansion can cause acute elevated IOP (particularly with C3F8 if concentration exceeds 16%), risking optic nerve damage. Anterior chamber paracentesis pre-injection and early post-operative IOP check mitigate this risk. Patients must not undergo nitrous oxide anaesthesia while gas is present (nitrous oxide diffuses into the bubble, causing dangerous expansion).

Fish-egg phenomenon (subretinal gas): Small bubbles of gas migrating into the subretinal space, which typically resolve spontaneously but can transiently complicate macular reattachment.

Cataract acceleration: Cryotherapy or gas-lens contact can occasionally precipitate posterior subcapsular cataract in phakic eyes, though this is less common than after vitrectomy.

Endophthalmitis: Rare (<0.05%) but sight-threatening infection following any intravitreal injection, including pneumatic retinopexy. Strict sterile technique, povidone-iodine preparation, and antibiotic eye drops reduce risk.

Air travel and altitude restriction: SF6 is present for 7–14 days; C3F8 for 4–8 weeks. Patients must not fly, ascend above 1,000 metres in altitude, or undergo nitrous oxide anaesthesia until confirmed gas absorption, due to bubble expansion risk causing acute-angle closure glaucoma and central retinal artery occlusion.

Intensive follow-up in the early post-procedure period is essential for pneumatic retinopexy success, as the procedure depends on patient positioning compliance and early laser application.

Day 1 review (24 hours post-injection): Critical assessment includes:

• Indirect ophthalmoscopic confirmation that the gas bubble is in contact with the causative break (break-up tamponade)
• Fundal assessment for retinal reattachment or persistent subretinal fluid
• IOP measurement (target <25 mmHg; treat elevated IOP with topical beta-blockers or carbonic anhydrase inhibitors if needed)
• Central retinal artery patency (light perception present)
• Laser photocoagulation if the break is accessible and IOP is controlled

Week 1 follow-up: Indirect ophthalmoscopy to assess retinal reattachment status, gas bubble size (reduces by approximately 50% over 5 days), subretinal fluid resolution, and laser/cryo adhesion. Additional laser burns may be added around incompletely sealed break margins. Any new inferior subretinal fluid or new peripheral breaks must be identified and managed promptly.

Month 1 follow-up: Once gas is fully absorbed (confirmed by absence of bubble reflex on fundoscopy), full fundal examination under maximal mydriasis to confirm complete reattachment, integrity of laser/cryo scar, and exclusion of new breaks in the treated or fellow eye. Visual acuity, IOP, and lens clarity are documented.

Re-detachment management: If pneumatic retinopexy fails — either immediately (non-attachment) or after initial success (re-detachment) — salvage with pars plana vitrectomy is the standard approach, with or without scleral buckle depending on break characteristics and PVR status. A second pneumatic retinopexy may be attempted for new superior breaks without PVR if the failure was due to a missed peripheral break rather than positioning non-compliance or PVR. Post-pneumatic retinopexy vitrectomy success rates remain high (85–95%), so patients can be reassured that procedural failure does not compromise final visual outcomes.

Fellow eye monitoring: Patients who have had an RRD in one eye have a 5–15% lifetime risk of RRD in the fellow eye. Regular annual dilated fundal examination of the fellow eye with prophylactic laser to symptomatic lattice degeneration or atrophic holes reduces this risk.

One of the most compelling advantages of pneumatic retinopexy is its substantially lower cost compared to theatre-based RRD repairs, making it an important option both in resource-constrained healthcare systems and in private or co-pay settings.

Procedure cost comparison:

• Pneumatic retinopexy: £500–£1,500 in the private UK sector; $1,000–$3,500 USD in the US. In public NHS settings, cost is estimated at £500–£900 per episode including clinic visits.
• Pars plana vitrectomy (PPV): £3,000–£6,000 private UK; $8,000–$15,000 USD. NHS cost £2,500–£4,500 including theatre and anaesthesia.
• Scleral buckling: £2,500–£5,000 private UK; $7,000–$12,000 USD.

Cost drivers unique to pneumatic retinopexy:

• Intravitreal gas (SF6, C3F8) is inexpensive in bulk but requires appropriate handling and dedicated gas preparation equipment
• Multiple clinic visits in the first week (Day 1, Day 3–5, Day 7, Day 14) add visit costs but are typically far less than theatre time
• Positioning equipment (face-down chair, face-down pillow systems) costs $100–$500 USD and may be rented from some clinics; this patient-born cost should be factored into counselling

Global access: In low- and middle-income countries (LMICs) where retinal surgery theatre time is severely limited, pneumatic retinopexy provides a lifeline for timely RRD repair. Many high-volume public ophthalmology hospitals in India, sub-Saharan Africa, and Latin America have incorporated pneumatic retinopexy into their RRD care pathway for appropriately selected patients, substantially reducing waiting lists for vitrectomy while achieving comparable visual outcomes.

Insurance coverage: Pneumatic retinopexy is covered by most health insurance systems and public health services as an established RRD treatment. Specific CPT code 67110 (repair of retinal detachment, by injection of air or other gas) applies in US Medicare/Medicaid billing. UK NHS patients with appropriate selection criteria can access pneumatic retinopexy via a rapid-access retinal detachment pathway.

Two established surgical alternatives to pneumatic retinopexy exist for rhegmatogenous retinal detachment, each with distinct anatomical success profiles, complication risks, and appropriate indications:

Pars Plana Vitrectomy (PPV):

• The most commonly performed RRD repair in high-income countries. Involves removal of vitreous gel, direct visualisation and treatment of all retinal breaks under endoscopic illumination, internal drainage of subretinal fluid, endolaser photocoagulation, and tamponade with gas bubble or silicone oil.
• The PIVOT trial demonstrated superior single-procedure anatomical success for PPV vs. pneumatic retinopexy (90% vs. 76%), but equivalent final visual acuity at 12 months (mean Snellen equivalent: 20/40 both groups) and higher rates of cataract formation in the PPV arm in phakic patients.
• PPV is preferred for: inferior or posterior breaks, multiple breaks in different clock-hour quadrants, significant vitreous haemorrhage, PVR, giant retinal tears, combined tractional-rhegmatogenous detachments, and patients unable to comply with positioning.

Scleral Buckling:

• A purely extraocular procedure placing a silicone sponge or band (buckle) on the outer scleral surface, permanently indenting the eye wall to bring the retinal pigment epithelium into contact with the neurosensory retina around the break and relieve vitreoretinal traction. The subretinal fluid resorbs over 1–4 weeks.
• Advantages over vitrectomy: does not disturb the lens (important in young phakic patients), no gas or oil tamponade required, avoids cataract formation, long-term tamponade is permanent (the buckle remains in place lifelong).
• Preferred for: young phakic patients with inferior or anterior breaks, lattice-related detachments without posterior extension, and detachments with extensive vitreous base pathology where vitrectomy access is limited.
• Complications include: buckle infection (1–2%), buckle extrusion or migration (rare), diplopia from extraocular muscle imbalance, induced myopia (axial length increase), and choroidal detachment.

Combined pneumatic retinopexy and buckling: Rarely used; combined approach may be considered when some inferior breaks coexist with superior detachment requiring gas tamponade.

Observation: For asymptomatic lattice degeneration without detachment, prophylactic laser is the standard; observation without intervention is appropriate for low-risk lattice in patients without fellow-eye detachment history.